Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Conclusions Dapagliflozin was associated with improvements in body composition, most likely a reduction in visceral fat, which occurred together with improvements in liver tests and metabolic variables in patients with NASH-associated with T2DM. UMIN Clinical Trial Registry identifier: UMIN000023574.
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Forxiga | Insulin | Laboratory Medicine | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | SGLT2 Inhibitors | Study | Urology & Nephrology